Welcome Remarks / Opening Remarks
Welcome Remarks 
Dr. Koichi Akashi
Opening Remarks 
Dr. Norio Komatsu
Basic Science of MPN
Mutations in MPN: Hereditary Predispositions, Disease Initiators and Drivers of Progression 
Dr. Robert Kralovics
The Role of Wild and Mutant Calreticulin in Hematopoiesis 
Dr. Kazuya Shimoda
Molecular Mechanisms Leading to the Development of Myeloproliferative Neoplasms by Mutant Calreticulin 
Dr. Marito Araki
The role of HMGA2 in MPN 
Dr. Chih-Cheng Chen
MPN Pathology
New WHO Classification of Myeloproliferative Neoplasms 
Dr. Hans-Michael Kvasnicka
Hot Topic of MPN
MPN Disease Burden: Lessons Learned from Patients 
Dr. Ruben Mesa
Asian MPN Session
Childhood Myeloproliferative Neoplasms 
Dr. Jong Jin Seo
Clinical Outcomes of Patients with Primary Myelofibrosis in Japan: A Report of a Nationwide Survey from 1999 to 2015 
Dr. Katsuto Takenaka
Primary Myelofibrosis in Taiwan 
Dr. Lee-Yung Shih
Chronic Neutrophilic Leukemia: Experience from China 
Dr. Qian Jiang
IFN Renassiance
IFN Treatment for PV 
Dr. Richard Silver
Long Term Results of Peg-IFN Therapy in PV and ET 
Dr. Srdan Verstovsek
Results of the PROUD-PV Study 
Dr. Heinz Gisslinger
Molecular Landscape of MPN: Influence on Response to Therapy and Evolution Under Treatment with Interferon Alpha 
Dr. Bruno Cassinat
Can We Alter MPN Evolution with IFN Therapy? 
Dr. Jean-Jacques Kiladjian
New Antiviral Mechanism of Interferon on Hepatitis B virus 
Dr. Pei-Jer Chen
Panel Discussion
Panel Discussion 
Chair: Dr. Jean-Jacques Kiladjian & Dr. Srdan Verstovsek
Closing Remarks
Closing Remarks 
Dr. Kazuya Shimoda